You are here

  • Home
  • Archive
  • Volume 73, Issue 8
  • Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody

Article Text

Article menu
Download PDFPDF
Letters
Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody
  1. Jing Zou1,
  2. Ting Li2,
  3. Xingfang Huang2,
  4. Sheng Chen2,
  5. Qiang Guo2,
  6. Chunde Bao2
  1. 1 Department of Pneumology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
  2. 2 Department of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
  1. Correspondence to Professors Chunde Bao and Qiang Guo, Rhematology Department of Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, No.145, Shangdong (c) Road, 200001, Shanghai, China; baochunde_1678{at}126.com and marquisjerry{at}126.com

https://doi.org/10.1136/annrheumdis-2014-205278

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Clinical amyopathic dermatomyositis (CADM) is a special spectrum of dermatomyositis; there is prominent skin disease, but minimal or absent muscle disease.1 Rapidly progressive interstitial pneumonia (RPIP) in CADM has been reported predominantly in Asia. In contrast, Cottin et al2 reported a benign course of interstitial pneumonia in European patients with CADM. The treatment of CADM accompanied with RPIP is challenging, complicated by its rarity and heterogeneity. Generally, this condition is resistant to therapy and commonly fails to respond to aggressive therapy, such as high-dose corticosteroids and immunosuppressants and has a very poor outcome and prognosis.3–⇓⇓6 Interleukin 2 receptor α chain (IL-2Rα, or CD25), a high affinity receptor, is expressed on T and B lymphocytes after their activation. Little IL-2Rα is expressed on unstimulated lymphocytes or is found as soluble IL-2 receptor (sIL-2R) in the serum of healthy people, however, increases in sIL-2R are seen in the setting of autoimmune diseases. …

    View Full Text

    Footnotes

    • JZ and TL contributed equally to this article.

    • Acknowledgements The authors thank all the families for participating.

    • Contributors All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. CDB and QG were involved with conception and design, JZ and TL, acquisition of the data, and JZ, TL, SC and XFH, analysis and interpretation of the data. JZ and TL contributed equally to this article.

    • Competing interests None.

    • Patient consent Obtained.

    • Ethics approval The local ethics committee at Renji Hospital, Shanghai Jiao Tong University School of medicine.

    • Provenance and peer review Not commissioned; externally peer reviewed.